IMI AMR ACCELERATOR

𝗛𝗼𝘄 𝘁𝗼 𝘁𝗿𝗮𝗰𝗲 𝗧𝗕 𝗱𝗿𝘂𝗴 𝗺𝗲𝘁𝗮𝗯𝗼𝗹𝗶𝘀𝗺 𝘄𝗶𝘁𝗵𝗼𝘂𝘁 𝗿𝗮𝗱𝗶𝗼𝘁𝗿𝗮𝗰𝗲𝗿𝘀? With more safer and faster approach?
Researchers under TRIC-TB consortium used ¹⁹F-NMR, ¹H-NMR & HR-MS to profile alpibectir.

👉 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗽𝗮𝗽𝗲𝗿 𝗮𝘁 https://bit.ly/4muyHLJ

Everyone in the antimicrobial resistance ecosystem stands to gain clearer direction, better tools and stronger collaboration with this WHO roadmap (2024–2030).

AMR is not just scientific or clinical problem, but a systemic challenge needing multisectoral solutions.

🔗 https://bit.ly/4opZATc

TB survives by fueling its metabolism through a tricky enzyme, cytochrome bc1:aa3.

So how do we starve it?
Inhibiting isn’t enough, we need to know exactly how it’s blocked.

Our new study under Respiri TB, reveals this in detail.
👉 Swipe to learn more
🔗 Full paper: https://bit.ly/4oeme0A

@era4tb.bsky.social

Last week, we got together to focus on a key part of TB research: advancing animal models. Six ERA4TB experts discussed how ethical animal models can drive better treatments for drug-resistant TB and speed up testing of new therapies. While the webinar was internal, the impact is global.

The honest reality check on AMR transmission models every researcher needs. Clarity on what works, what is missing and how to build trust.

👉 Swipe to learn the insights
👉 Read more: bit.ly/46UMqXO

#AMR #TB #antimicrobialresistance #research

@era4tb.bsky.social @ihieurope.bsky.social

Juan Calvet (@uc3m.es) presented a poster on the integration of molecular biomarkers into time-kill assays for evaluating new anti-TB drug candidates.

@amr-accelerator.bsky.social
@ihieurope.bsky.social
#Tuberculosis #TB #TranslationalResearch #Biomarkers #TimeKillAssays

I was taking 23 pills every day for 10 months.” A TB survivor shared this at ERA4TB’s MDR-TB dialogue. Behind every protocol is a person. That’s why we say “people affected by TB” or “TB survivors”. Language shifts power, from object to partner. Research must listen and build with communities.

We can’t fight 21st-century superbugs with 20th-century methods. Machine learning now predicts not just if a molecule is antimicrobial, but what class it targets. A COMBINE study shows how ML speeds smarter screening in early discovery.
👉 Swipe to learn more
👉 Read at: https://bit.ly/3GOfqFW

Immigration to Europe rose 33–50% in a decade. But, TB rates in migrants dropped by 28%. The concern of most of TB cases among immigrants is because native TB fell sharply and migrants often come from TB-endemic regions.

Learn more from the discussion conducted by UNITE4TB: https://bit.ly/3UcaAFA

Great things happen in great partnerships, especially public–private ones. But not all are complete… yet!

The AMR Accelerator asks:
How can Europe bridge key gaps in antimicrobial resistance research?

👉 Read the new open access paper now: https://bit.ly/3TqqSdM

@era4tb.bsky.social @ihieurope.bsky.social @callmetube.bsky.social @antimicrobial.bsky.social @arom-ntu.bsky.social @wwtb-uk.bsky.social

We are proud to be a part of a scientific data management platform called 𝗴𝗿𝗶𝘁, grit42’s open-source data platform. Via the COMBINE, GNA NOW & ERA4TB projects, we aim to make our scientific research more collaborative and impactful for all.

👉 For details: https://bit.ly/3TQOati

𝗦𝗮𝗺𝗲 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲, 𝗱𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝘁 𝗼𝘂𝘁𝗰𝗼𝗺𝗲𝘀.
How do we get TB dosing right for everyone?

Our latest UNITE4TB study, led by Andrii Dudnyk, shows how drug monitoring & modelling support safer and smarter TB treatment.
🔗 bit.ly/4nv255T
July 3, 2025 at 7:10 AM

Hear from Quentin Leclerc, as he shares how he’s using data, equations and tools to guide AMR interventions

In this interview, he talks about:
🔬 Data-driven Modelling
🤝 Cross-disciplinary Collaboration
💡 Innovative Problem-Solving

🔗 Read full interview: https://bit.ly/3ZV5hxE

𝗦𝗵𝗮𝗿𝗶𝗻𝗴 𝗱𝗮𝘁𝗮 𝗶𝘀 𝘁𝗼𝘂𝗴𝗵. 𝗥𝗲𝘂𝘀𝗶𝗻𝗴 𝗶𝘁? 𝗘𝘃𝗲𝗻 𝘁𝗼𝘂𝗴𝗵𝗲𝗿!
Our new PrIMAVeRa study, explores how mAbs & vaccines impact antimicrobial resistance and tackles the real-world roadblocks to data sharing with practical fixes.

👉 What’s getting in the way? How do we solve it?

Hear from Carina Matias, as she shares her contribution is shaping reproducibility and clinical relevance in AMR research via COMBINE Project.

In this interview, she provides insight into:
🧪 Drug Development
🤝 Global Collaboration
💻 AI Discovery

🔗 Read full interview: https://bit.ly/4lknOvI

𝗛𝗼𝘄 𝗰𝗮𝗻 𝘄𝗲 𝗺𝗲𝗮𝘀𝘂𝗿𝗲 𝗧𝗕 𝗯𝗮𝗰𝘁𝗲𝗿𝗶𝗮 𝗺𝗼𝗿𝗲 𝗿𝗲𝗹𝗶𝗮𝗯𝗹𝘆?
This work presents a protocol that combines two methods to better quantify MTB in time-kill assays.

🔍 More accurate data = better TB drugs.
⠀
👉 𝗦𝘄𝗶𝗽𝗲 𝘁𝗼 𝘀𝗲𝗲 𝗵𝗼𝘄 𝘄𝗲 𝗱𝗼 𝗶𝘁.

@era4tb.bsky.social

Don't miss the chance to attend the UNITE4TB webinar!

Join to learn on revolutionizing TB diagnosis: moving beyond sputum with innovative, noninvasive tools that improve detection, guide care and drive change.
 
🗓️ 26 June 2025
⏰ 13:00-14:00 CEST
 
🔗 Register now: bit.ly/3FG8sm7

Same medicine, but different outcomes.
Why does this happen and what can we do about it?

In our recent work, we unpack interoccasion variability. A key factor in how we model drug behavior and build smarter clinical studies.

👉 Swipe to learn more.

Hear from Leonie von Berlin, as she shares how FAIR data practices power innovation across AMR Accelerator projects.

In this interview, she talks about
🧬 Unified infrastructure
🤖 Enabling ML in antimicrobial R&D
🌍 Promoting open, global science

🔗 Read full interview: https://bit.ly/45zTOaD

Good luck to all the ERA4TB consortium members presenting at PAGE 2025 this week.

www.page-meeting.org/default.asp?...

#TBSky #TBResearch #Tuberculosis

How far can a petri dish take us in the fight against MRSA? 🧫
Using translational modelling, from in vitro to mouse models, we go further than you’d think !

Have a look at:
🔍 What we did
💡 Why it matters
🚀 Where it leads

More about the paper on our site. amr-accelerator.eu/publications/

How is ML shaping smarter drug discovery? 💊
In our recent young researchers interview, Yojana Gadiya shares her work on an ML-powered Antimicrobial Knowledge Graph, FAIR MIC dataset and the promise of generative models. Full interview: amr-accelerator.eu/news/intervi...

@fraunhoferitmp.bsky.social

A flexible multi‐metric Bayesian framework for decision‐making in Phase II multi‐arm multi‐stage studies We propose a multi-metric flexible Bayesian framework to support efficient interim decision-making in multi-arm multi-stage phase II clinical trials. Multi-arm multi-stage phase II studies increase t....

Even with sparse data & imperfect surrogates, a flexible Bayesian framework can guide early decisions in MAMS Phase II trials. Via UNITE4TB.

📄 Read the complete paper at: bit.ly/43wjZfw
ℹ️ For more information: bit.ly/42Yob7r

#ClinicalTrials #AMR #TB #tuberculosis

Recently, our experts discussed endolysins, from concept to first-in-human trials and shared insights on breakthroughs, challenges & the future of antimicrobials.

📺 Watch: bit.ly/43u5bxV
🌐 Learn more: bit.ly/43eNkfG

#AMR #webinar #Biotech

And the ERA4TB 9th Consortium Meeting is over!

Thanks to our host, @www.unizar.es, all our partners, our key-note speakers and the Scientific Advisory Board members for their attendance and insightful contributions.

@pasteur.fr @amr-accelerator.bsky.social @ihieurope.bsky.social

Towards comprehensive clinical trials for new tuberculosis drug regimens: policy recommendations from a stakeholder analysis Background Research and development (R&D) of new drugs and regimens against tuberculosis (TB) is evolving to meet new challenges and face limited investments in the sector. To effectively improve and ...

Must Read: As TB remains a global challenge, drug trial innovation must center voices who face the barriers. A research by Villa S. et al. (UNITE4TB Consortium) offers policy steps for more inclusive, effective TB trials.

🔗 Paper: bit.ly/4mrlV1A
🔗 Info: bit.ly/42Yob7r

‪@antimicrobial.bsky.social‬‬‬
@ineosoxford.bsky.social
@isacworld.bsky.social
@dhh-amr.bsky.social
@bsacandjac.bsky.social
@dhh-amr.bsky.social‬
@bsacandjac.bsky.social‬
@isacworld.bsky.social‬
@ihieurope.bsky.social
@era4tb.bsky.social